Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280959 | 1.00 | CYP3A4 (0.59) | CYP3A4CYP2C9TBXAS1KCNH2CCNE1 | |
| SCHEMBL2274215 | 0.82 | CYP3A4 (0.64) | CYP3A4CYP2C9TBXAS1ALOX5PTGES | |
| SCHEMBL2274219 | 0.82 | CYP3A4 (0.64) | CYP3A4CYP2C9TBXAS1ALOX5PTGES | |
| SCHEMBL1093086 | 0.79 | CYP3A4 (0.64) | CYP3A4CYP2C9TBXAS1CCNE1CDK2 | |
| SCHEMBL1093084 | 0.79 | CYP3A4 (0.64) | CYP3A4CYP2C9TBXAS1CCNE1CDK2 | |
| SCHEMBL2277729 | 0.78 | CYP3A4 (0.59) | CYP3A4CYP2C9TBXAS1KCNH2 | |
| SCHEMBL2277727 | 0.78 | CYP3A4 (0.59) | CYP3A4CYP2C9TBXAS1KCNH2 | |
| SCHEMBL58024 | 0.76 | CYP3A4 (1.00) | CYP3A4CYP2C9TBXAS1CES2CES1 | |
| SCHEMBL58023 | 0.76 | CYP3A4 (1.00) | CYP3A4CYP2C9TBXAS1CES2CES1 | |
| SCHEMBL1092835 | 0.76 | CYP3A4 (0.68) | CYP3A4CYP2C9TBXAS1ALOX5PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190283-A1 | Fab I Inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190283-A1 | Fab I Inhibitors | SERPINB1, TFPI, TFPI2 | CYP3A4 2080/4885CYP2C9 1989/4885TBXAS1 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.